Interactive tool
Choosing a venoactive drug
Enter the predominant clinical picture and the patient's conditions: the tool ranks the drugs by priority, separates cautions from contraindications and prepares the text for the report. Everything runs in the browser, without transmitting or storing any data.
Step 1
Clinical picture
Select the predominant picture: it determines both the non-pharmacological basis and the list of drugs assessed.
Chronic venous disease
Lymphoedema and thrombotic conditions
Clinical detail
The CEAP class is pre-filled from the clinical picture and can be changed; it appears in the report text. The ulcer fields appear only when needed and change the rationale for MPFF and pentoxifylline.
Step 2
Risk factors and conditions
Tick everything that applies: it determines cautions and exclusions, and brings up the cross-cutting alerts.
Step 3
Text for the report
A ready-made sentence to paste into the conclusions. It remains a recommendation, not a description of ongoing therapy.
Interpretation
How to read the result
The proposal reads from top to bottom, in the order in which the decisions are actually made. The non-pharmacological basis comes first because it is the treatment: compression, exercise, skin care, weight loss. The alerts that follow are the checks to make before writing a prescription. Only then do the drugs appear, ranked by priority within each group.
Indicated: none of the selected conditions interferes. Caution: the drug can still be used but the risk/benefit balance must be reassessed, and the reason is always stated. Avoid: there is a contraindication. An excluded drug remains visible with its reason, because the exclusion is itself clinical information — and because a contraindication must never be downgraded to a warning.
A: RCTs or meta-analyses with consistent results on the outcome considered. B: controlled studies of smaller size or lower quality, or a surrogate outcome. C: consensus, extrapolation or purely symptomatic relief. The label refers to the individual drug in the individual clinical picture, not to venoactive drugs as a class: that is the reason this page exists.
It does not calculate weight-based doses, does not check drug interactions, does not know the patient's renal function and does not decide whether to anticoagulate: in SVT and DVT the key decision is a different one and belongs in the anticoagulant selector. It does not write into the report: it produces a text to copy.
Bibliography
Sources
- ESVS 2022 — De Maeseneer MG et al., Clinical Practice Guidelines on the Management of Chronic Venous Disease of the Lower Limbs (Eur J Vasc Endovasc Surg 2022;63:184–267): general recommendation on venoactive drugs and on adjuncts for venous ulcer, both Class IIa, Level A.
- SVS / AVF / AVLS 2023 — Gloviczki P et al., guidelines on varicose veins of the lower extremities, Part II.
- Cochrane reviews — pentoxifylline in venous leg ulcer (Jull 2012), horse chestnut seed extract (Pittler 2012), benzopyrones in lymphoedema (Badger 2004), superficial vein thrombosis (Di Nisio 2018).
- MPFF meta-analysis — Coleridge-Smith P, Lok C, Ramelet AA (Eur J Vasc Endovasc Surg 2005;30:198–208).
- SURVET — Andreozzi GM et al., sulodexide for the prevention of recurrent VTE (Circulation 2015;132:1891–7).
- SIAPAV 2025 — Delphi consensus on venoactive nutraceuticals (Nutrients 2025;17(24):3830).
- SmPCs of the individual medicines — AIFA database (Italy).
A quick-reference tool for healthcare professionals. It does not replace the original guidelines, the summaries of product characteristics or the specialist's clinical judgement. Always check licensed indications, dosage, contraindications, interactions and reimbursement in the current SmPC. No data entered on this page are transmitted or stored: everything stays in the browser and is lost when the page is closed.